The Role of Endoproteolytic Processing in Neurodegeneration by Wilson, Cornelia M et al.
Review: 
 
"The role of endoproteolytic processing in neurodegeneration"   
Mohammed Kamala, Cornelia M. Wilsonb* et al... 
 
aKing Fahd Medical Research Center, King Abdulaziz University, P.O. Box: 80216, 
Jeddah - 21589, Kingdom of Saudi Arabia 
bEA3842 Homéostasie cellulaire et pathologies and Chaire de pneumologie 
expérimentale, Université de Limoges, Faculté de Médecine, 2, rue du Dr Raymond 
Marcland, 87025 Limoges CEDEX–France 
 
*To whom correspondence should be addressed. 
E-mail: cornelia.wilson@unilim.fr 
 
Running title: Endoproteolytic cleavage and neurodegeneration 
Total character count: 18,266 (no spaces): 21,562 
 
  
Key words: Alzheimer’s disease, Endoproteolytic cleavage, Huntington’s disease, 
Prion disease 
 
Abstract: 
Endoproteolysis is a normal post-translational process in the eukaryotic cell and has 
played a role early on in protein evolution allowing protein catabolism and the 
generation of amino acids. Endoproteolytic cleavage regulates many crucial cellular 
processes including the activity of many proteins, their protein-protein interactions, 
the amplification of cell signals etc. Not surprisingly, disruption or alternation of 
endoproteolytic cleavage maybe the root cause of many human diseases such as 
neurodegeneration including Alzheimer’s disease, Huntington’s disease and prion 
diseases. Most neurodegenerative diseases (ND) are caused by the build-up of 
misfolded proteins and the promotion of aggregation events. A common event that 
occurs in these ND is the alteration of endoproteolytic cleavage by genetic mutations 
of the associated-proteases or in the target substrate. Endoproteolytic cleavage 
resulting in protein truncation has significantly consequences on the structure and 
function of a protein representing a common feature of ND.  In this review, we will 
discuss the endoproteolytic cleavage events that lead to ND namely Alzheimer’s 
disease, Huntington’s disease and prion diseases. 
  
Overview of endoproteolytic cleavage 
Endoproteolytic cleavage is the break down of proteins into smaller polypeptides or 
amino acids. A process accelerated through mainly the action of proteases. The 
physiological function of proteolysis can provide nutrients for the organism or be a 
means to control the activity of a protein after protein synthesis. This process is 
important for cellular homeostasis allowing the regulation of cellular processes as 
well as removing the build up of unwanted protein products that would be toxic to the 
cell. Not surprisingly, deregulation of endoproteolysis can result in a number of 
human diseases such as pancreatitis, diabetes mellitus, Alzheimer’s disease (AD), 
prion diseases, emphysema, muscular dystrophy to name a few. For this review, we 
will focus on the deregulation of proteolysis in neurodegenerative diseases namely, 
Alzheimer’s disease, Huntington’s disease (HD), and Prion diseases. 
Alzheimer’s disease 
Alzheimer disease (AD) is clinically defined by the loss of neurons and the 
emergence of two forms of protein aggregates: senile plaques and neurofibrillary 
tangles [1]. AD is a sequential and progressive disease of the brain resulting in the 
irreversible loss of neurons. The effect has a profound consequence on the affected 
individual with the loss of intellectual abilities especially the memory and the means 
to reason hindering the person’s normal life activities and cognitive function. 
APP processing 
Amyloid-β protein (Aβ) is mainly found in senile plaques. Aβ is generated from its 
precursor called amyloid precursor protein (APP) via sequential cleavage by the β- 
and γ-secretases [2] (Figure 1). Notably, genetic mutations observed in patients of 
mainly the inherited form of familial AD resulted in either an increase of production 
and/or Aβ aggregation, indicating that Aβ is a seed of AD pathogenesis. Specifically, 
the C-terminal region of Aβ shows diversity and the longer Aβ peptide is principally 
deposited in AD patient brains [3]. Therefore, the γ-secretase has become a major 
molecular target in drug discovery of AD. Nevertheless, the putative APP γ-cleavage 
sites relate to amino acid residues located to the transmembrane domain (TMD), and 
thus it has taken more than a decade of research to advance our current understanding 
of the γ-secretase, which performs endoproteolysis within the TMD [4]. Firstly, the 
genes to be identified by genetic analyses of the familial form of AD were those of 
the multi-spanning membrane protein encoding called presenilin (PS) 1 and 2 [5]. 
Remarkably, the missense mutations causing disease were likely to change γ-secretase 
cleavage of APP resulting in elevated production of aggregation-prone Aβ-form 
(Aβ42) as compared with the other main Aβ species, Aβ40 [6, 7]. Secondly, the 
ablation of presenilin eliminated cleavage by the γ-secretase cleavage of APP [8, 9] 
and the intra-membrane aspartates found in PS TMD-6 and TMD-7 are necessary for 
Aβ production [10]. A number of cross-linking approaches showed that γ-secretase 
inhibitors (GSIs) directly implicated and targeted the PS proteins [11, 12]. Lastly, the 
perturbed function of the clathrin assembly lymphoid myeloid leukaemia gene protein 
(CALM) that is encoded by the phosphatidylinositol binding clathrin assembly 
protein (PICALM), altered the lysosomal localisation of the γ-secretase and in turn 
the production of Aβ42 [13, 14]. These studies demonstrate that PS possesses the 
catalytic activity resulting in γ-secretase intramembrane cleavage of APP and thus 
affects AD pathogenesis.  
 PS is part of a family of intramembrane proteases (IMP) that are distinguished 
by the topology of their transmembrane domain and also by nature of the membrane 
active site amino acid residues. The aspartate IMPs are located to two catalytic 
aspartate amino acid residues found in PSs, signal peptide peptidase (SPP), and SPP-
like (SPPL) proteases [15, 16]. The catalytic aspartate of IMPs is located within the 
Gly-X-Gly-Asp motif and hence these proteases are known as the GXGD-type 
proteases [17]. The GXGD motif is conserved in type 4 prepilin peptidase proteins, 
and is prerequisite for many bacterial protease cleavages. Interestingly, SPP was 
originally identified by a chemical biology approach and contains the same GXGD 
motif but differs according to its primary sequence and topology [18]. Nevertheless, 
expression of PS alone is not sufficient to reconstitute the γ-secretase activity. A 
number of genetic and biochemical studies followed that demonstrated that PS 
required three further partners, nicastrin [19], anterior pharynx-defective 1 (Aph-1), 
and presenilin enhancer-2 (Pen-2) [20]. These subunits of the γ-secretase associate in 
a 1:1:1:1 stoichiometry [21] and co-expression of these binding partners along with 
PS was sufficient to reconstitute the γ-secretase activity.[22, 23]. The activity of the γ-
secretase complex is regulated by an auto-endoproteolysis cleavage event of PS 
between the TMD-6 and TMD-7 generating N- and C-terminal fragments [24] that 
only associate with γ-secretase inhibitors or demonstrate strong proteolytic activity 
[12, 25]. The activity through this auto-endoproteolysis is regulated by an unknown 
mechanism. Our studies have defined that subunits of the oligosaccharyltransferase 
DC2 and KCP2) complex normally involved in N-glycosylation of proteins at the ER 
can regulate PS endoproteolysis to promote γ-secretase activity [26]. 
 
 
Tau protein and neurofibrillary tangles 
The other contributing factor to AD is the emergence of tau protein snarls found in 
neurofibrillary tangles that accumulate in AD and other dementias. Evidence is 
growing to indicate that the soluble form of tau does the most damage in 
neurodegeneration [27]. On one hand, a study has shown that tau ‘stickiness’ is 
because of its ability to aggregate that contributes to its toxicity [28].  
Tau truncation 
Tau protein is naturally an intrinsically disordered protein singly encoded by 
Microtubule-Associated Protein Tau (MAPT) gene located to the chromosome 17q21 
in humans [29] (Figure 2). Tau protein is mainly expressed in the axons of neurons of 
the central nervous system (CNS) and also found in other cell types in the CNS [30]. 
In the adult human brain, tau mRNA is spliced with or without three regions encoded 
by exon 2, exon 3 and exon 10, resulting in 6 different isoforms of tau [31, 32]. There 
is also alterative splicing of exon 10 yielding to tau isoforms containing 3 (3R) or 4 
(4R) imperfect MT-binding repeats in the C-terminal domain, which are both found in 
the tangles of tauopathy patient brains [33, 34]. The 3R and 4R isoforms are found in 
equivalent amounts in the healthy adult brain [35]. The longest form of human tau is 
441 amino acids long (Figure 2). Tau can be subdivided into two domains, the N-
terminal projection domain and the C-terminal microtubule-binding domain (MBD). 
The N-terminal domain of tau plays a role in signal transduction pathways through its 
interaction with proteins such as Phosphoinositide phospholipase C-γ (PLC-γ) and 
Sarcoma (Src)-kinases. The C-terminal domain, also known as the microtubule-
binding domain (MBD), controls the rate of polymerization of microtubules and that 
directly is involved in the association of functional proteins such as protein 
phosphatase 2A (PP2A) or PS1 [36]. Mutations found at the gene level in MAPT 
linked to inherited tauopathies are mainly grouped into two categories: mutations that 
affect the protein levels or mutations affecting mRNA splicing, leading to elevated 4R 
tau production. In addition, many mutations found in exon 10 can effect both the 
protein and the RNA levels of tau [37]. 
In the eukaryotic cell the MT cytoskeleton is an important network providing a role 
for many cellular processes such as motility, morphogenesis, mitosis, meiosis, and the 
trafficking of organelles and macromolecules. The major constituent of MTs is the 
heterodimer of α- and β-tubulin proteins. The nature of MT is highly dynamic but 
they present with a non-equilibrium behaviour often termed dynamic instability [38]. 
The MTs adopt rapid stochastic transition through growth and shortening, as an effect 
of the interaction of the heterodimer of tubulin dimers at its ends. This provides a 
mechanism for Tau protein to promote tubulin polymerisation and thus stabilize MTs 
[39-41]. The functional role of tau was initially shown to promote the assembly of 
MTs [39] and hence their stability and to associate with the cytoskeleton. Tau 
interacts strongly with MTs [42], and after associating with the MT via the repeat 
regions, stabilizes the MTs at the plus end, providing stability to the MTs during 
growth phases, whilst tau N-terminal domain may act as a ‘spacer’ region between tau 
and the MTs ensuring the correct distance between them [43-46]. Also, there are a 
number of studies that implicate and corroborate that tau enhances the stabilization 
and assembly MTs on one hand, and on the other, tau mutations alter the association 
of tau with MTs. For example, tau mutations such as G272V, DK280, P301L, P301S, 
L315R, G335V, V337M, and R406W alter tau’s ability to interact with the MTs 
affecting MT assembly with a direct affect upon the cytoskeleton and all the activities 
associated with this network [44, 47-51]. This could be due to an alteration in the 
phosphorylation status of tau that could be essential to regulate tau-MT interactions 
[52, 53], at the same time changes to the domain structure of the MT-binding site.  
Several cellular factors have been reported to affect tau aggregation, such as 
post-translational modifications including phosphorylation and acetylation (see 
review for further information [54]), and proteolysis, including the molecular 
chaperone machinery. Tau proteolytic cleavage could play an important role in tau 
aggregation. Caspases-3 and -6 can cleave tau at amino residue sites D421 and D348 
but caspase 3 has a greater efficiency [55]. In fact, tau cleavage site at D421 has 
already been observed in AD patient brains [55-57]. Furthermore, truncation of tau at 
D421 site accelerates tau aggregation compared to tau full length form [55] and this 
could act as a seed to initiating the process of aggregation of wild-type tau, as a 
mechanism prior to tangle formation [58, 59]. Tau cleavage by caspase does not 
impede hyperphosphorylation since both tau phosphorylation and truncation 
modifications are found in the brain of AD patients [55]. Furthermore, the D421-
cleaved tau form can be phosphorylated by GSK3β [58].  
In addition to caspase cleavage, tau can be cleaved by other types of proteases 
including cathepsins, calpains, and thrombin [59-62]. Pre-aggregated Aβ treatment 
results in tau truncation by calpain 1 generating a tau fragment 45 – 230 aa [59] that is 
commonly found in many tauopathies [63]. This fragment (45-230aa) of tau is 
particularly neurotoxic whilst other fragments generated by the calpain 2 protease is 
neuroprotective [59, 64] through their ability to form aggregates when arachodonic 
acid is present and thus perturbs aggregation of tau full length [63]. Recent studies 
have shown that tau could be cleaved by another type of protease called asparagine 
endopeptidase (AEP) also known as legumain (LGMN). AEP is a cysteine protease 
located to the lysosomes, which cleaves it substrates within the C-terminal region of 
the aspargine [65, 66]. The AEP protease is auto-activated and involves the removal 
of both C- and N-terminal pro-peptides at varying pH levels [67]. Tau protein 
undergoes cleavage by AEP at positions N255 and N368 [68]. This cleavage gives 
rise to several fragments that are unable to bind to MTs but can efficiently aggregate 
through the exposure of aggregation-prone tau residues i.e. 275-280 and 306-311 
[68]. These tau AEP-cleaved fragments are readily hyperphosphorylated [68]. 
Altogether, these studies demonstrate that tau can be cleaved by many proteases and 
the fragments generated may promote aggregation and toxicity, thus, contributing to 
the pathological events in AD.  
 
Huntington’s disease (HD) 
Huntington’s disease (HD) is a progressive inherited neurodegenerative disease which 
results in motor, cognitive and psychiatric symptoms [69]. HD is triggered by the 
expansion of the CAG repeat on chromosome 4 that encodes glutamine in the N-
terminal of huntingtin (Htt) [70]. The normal Htt gene has less than 36 CAG repeats 
whilst the abnormal Htt gene has more than 36 CAG repeats. For HD, the disease 
starts in the striatum in medium-spiny neurons and later penetrates deep into the 
cortex [69]. Htt protein is widely expressed in the CNS and in other non-neuronal 
tissues [71] and dispersed throughout the intracellular compartments [72-74]. The 
human Htt protein is a large protein with a molecular weight of 350 kDa and with 
3144 aa. It is made up of several domains including the HEAT (Htt, elongation factor 
3, the PR65/A subunit of protein phosphatase 2A and the lipid kinase Tor) domains 
that are 50 aa in length and consist of 2 anti-parallel α-helices that form a hairpin that 
is important for protein–protein interactions (Fig. 3). Approximately, 16 HEAT repeat 
domains have been found in Htt gene, which are arranged into clusters of 4 [75, 76]. 
The role and function of the HEAT domains for Htt is unknown. In addition, Htt 
contains 4 PEST sequences were the name is derived from P (proline), E (glutamic 
acid), S (serine) and T (threonine). 
Htt interacts with a number of proteins that play a role in apoptosis, vesicle transport, 
endocytosis, morphogenesis, cell signalling and transcriptional regulation. The 
function of Htt is believed to act as a scaffolding protein i.e. a bridge bringing its 
interacting partners in close proximity to allow signals to be transferred [77]. 
Interestingly, Htt has been shown to elevate the production of brain-derived 
neurotrophic factor (BDNF), a growth factor produced by striatal neurons [78]. 
Proteolysis in Huntington’s disease (HD) 
Htt protein is proteolytically cleaved at many sites generating several N-terminal 
fragments. Htt can be cleaved by several proteases including calpain, caspases, AEPs 
and matrix metalloproteases. Htt contains 2 calpain sites located at positions 469 and 
536 aa [79, 80] (Figure 3). Htt can be cleaved by several caspases such as caspase 3 at 
positions 513 and 552 aa [81, 82], caspase 2 at 552 aa [83] and by caspase 6 at 586 aa 
[82]. The matrix metalloproteinase, MMP-10 cleaves the Htt protein at 402 aa and is 
active in mice with HD [84]. The presence of the Htt fragments were the cleavage 
sites have been mutated promote lower toxicity of Htt indicating that proteolytic 
processing of Htt could contribute to HD pathogenesis [81, 85, 86]. Hence the 
proteolytic processing of Htt resulting in the generation of N-terminal fragments that 
contain polyglutamone tract could be a necessary stage in HD progression. This is due 
to the N-terminal fragments are more prone to aggregation and promote toxicity. 
These N-terminal fragments have been demonstrated to be present on both mouse HD 
models and in the brains of HD patients[80, 87, 88]. HD progression in HD mouse 
model have shown to be perturbed through the development of protease inhibitors or 
by mutating specific sequences important in Htt protease cleavage [82, 85]. However, 
the task to prevent all the proteolytic cleavages of Htt is difficult through the use of 
protease inhibitors and represents a therapeutic challenge for drug discovery. Future 
efforts should be targeted to identify the specific roles of the proteases and the effect 
of the N-terminal truncated fragments of Htt in HD progression and the implications 
in the pathological process. 
 
Prion diseases 
Prion diseases such as Creutzfeldt-Jakob disease in humans, scrapie in sheep and 
bovine spongiform encephalopathy in cattle, are all infectious and potentially fatal 
neurological conditions as a result of misfolding of cellular prion protein (PrPC) 
converted into a structurally different β-sheet-rich pathogenic isoform (PrPSc) that’s 
partially resistant to proteinase-K treatment and tend to aggregate [89]. The PrPC has 
a bipartite structure, N-terminal domain is disordered whilst the C-terminal domain is 
more structured containing 3 α-helices and 2 β-strands [90]. The function of PrPC is 
not clear but most studies indicate that PrPC could provide neuroprotection and it’s a 
neurotrophic protein [91]. PrPC neuroprotective function has been demonstrated in 
many in vitro and in vivo studies [92, 93]. These studies showed that the expression of 
PrPC was sufficient to slow down cell death and in other expression studies, PrPC 
could prevent cell death in stress conditions of serum deprivation of neurons [94]. 
Follow-on studies provided much evidence for PrPC implication in cellular survival as 
well as regulation of cell growth, proliferation, differenciation and stem cell 
expansion [95, 96]. 
 
Proteolysis in Prion diseases 
PrPC associates with the plasma membrane through a glycosyl-phosphatidylinositol 
(GPI) anchor. Early on after translocation into the endoplasmic reticulum, the N-
terminal signal peptide is removed by the signal peptidase followed by a C-terminal 
peptide before the attachment of a GPI anchor to the C-terminus. PrPC undergoes at 
least three proteolytic cleavage events after trafficking through the secretory pathway 
to the plasma membrane [97]. At the plasma membrane or in the endosomes, PrPC can 
be cleaved by an α-cleavage at position 110-111 and 112 aa to yield two products 
PrPC1, a product of 17kDa containing the GPI-anchor C-terminal fragment, and a 
11kDa N-terminal fragment that is released from the cell into the extracellular space 
(Figure 4). α-cleavage was first shown for the chicken PrP [98] and then in later 
studies shown in samples from humans [99]. The protease responsible for the α-
cleavage of PrPC is still unknown but is currently known as the α-PrPase [100]. 
However, the ADAM family could be involved in α-cleavage of PrP. ADAM10 and 
ADAM17 (also known as TACE) are implicated [101]. Also, ADAM9 [102] and 
ADAM8 [103] found in muscle could also be implicated in α-cleavage [104]. There 
still remains some controversy of which protease is directly involved and how this 
process is regulated [104]. It is thought that the cleavage event occurs in the 
endosome [105] or the late endocytic pathway [106]. α-cleavage occurs in normal 
brains with approximately 50% of C1 present compared to full length PrP [99]. PrPC 
can also undergo β-cleavage by a calpain protease at position 89-90 aa to produce 
PrPC2, a 20kDa fragment containing the GPI-anchor, and also a smaller 8kDa 
fragment known as PrPN2. β-cleavage of PrPC is a pathological event occurring at the 
plasma membrane in prion diseases which is promoted during conditions of oxidative 
stress such as the presence of reactive oxygen species. Also, some of PrPC is shed 
constitutively at the plasma membrane by the zinc metalloprotease called ADAM10 
[97]. Most evidence indicates that α-cleavage of PrP has a neuroprotective function as 
opposed to contributing to prion disease. Whilst β-cleavage by contrast to generating 
the C2 fragment is sufficient to support prion disease and appears to be abundant in 
the brains of prion-diseased individuals than in healthy ones [99], indicating that β-
cleavage could contribute to prion disease. However, it is likely that both types of 
cleavage have a role in prion disease but α-cleavage prevents PrP from converting 
into PrPSc. 
Summary 
Human NDs such as AD, HD and prion diseases are characterized by 
neurodegeneration that leads to a progressive functional decline. More than 20 million 
people worldwide are suffering from ND each year. This number of individuals with 
NDs is increasing rapidly, due to no effective therapy that is available. Thus, novel 
efficient therapy for ND is foremost unmet health need. NDs such as AD, HD and 
prion diseases greatly differ in respect of their clinical manifestation, duration, onset, 
etc.. Altogether, these human diseases share numerous common features such as 
altered protein cleavage, protein aggregation, oxidative stress etc. The major 
pathological event that is crucial and shared by many NDs such as AD, HD and prion 
diseases is proteolytic cleavage of disease-modifying proteins. Current evidence 
emerging shows that protein truncation is not only the driving force behind ND, but 
also serves as a seed for regeneration of novel truncated forms that finally speeds up 
the aggregation process leading to oligomeric assemblies of Htt and PrP, amyloid 
plaque, neurofibrillary tangle formation. To this end, we need to concentrate our 
efforts towards understanding the endoproteolytic processes and how to perturb these 
proteases without affecting cellular homeostasis. 
  
Figure legends 
Table 1 List of endoproteases in ND 
Table to show the substrates and their endoproteases associated to human 
neurodegeneration. 
Figure 1 APP processing 
(A) The schematic representation showing the domains of amyloid precursor protein 
(APP) and sites of endoproteolytic cleavage. (B) The amyloid precursor protein 
(APP) processing pathways. The APP protein transmembrane can be processed via 
two pathways, the non-amyloidogenic α-secretase pathway (no plaque formation) or 
the amyloidogenic β-secretase pathway (plaque formation). The non-amyloidogenic 
pathway results in the α-secretase cleaving β-amyloid (Aβ) in the centre to release a 
soluble fragment of APP called sAPP-α. Following this cleavage the APP C-terminal 
fragment 83 (APP-CTF83) is cleaved further by the γ-secretase to release two 
fragments, the APP intracellular domain (AICD) and the P3 fragment. The 
amyloidogenic pathway results in the β-secretase cleaving APP to generate a soluble 
fragment called the sAPP-β. The CTFβ is then cleaved by the γ-secretase to generate 
Aβ40, Aβ42 and AICD. 
 
Figure 2 Tau truncation 
Schematic representation of the functional domains of the longest tau isoform (441 
amino acids). Tau protein can be divided into two domains, the N-terminal projection 
domain, including an acidic and a proline-rich region and a C-terminal microtubule 
binding domain (MBD). The MBD contains three or four repeats (R1-R4) with a 
flanking N-terminal proline-rich region extending into the projection domain that 
contains most of the Ser/Thr-Pro motifs.  The endoproteolytic cleavage sites are 
indicated. 
Figure 3 Htt cleavage sites 
Schematic representation of the Htt protein. The full-length htt protein consist of 3144 
amino acids, with a molecular weight of 350kDa. The N-terminal region contains 17 
amino acid (N17) contains many post-translational modifications including sites for 
phosphorylation and ubiquitination. Immediately after the N17 region are the 
polyglutamine (polyQ) and polyproline (polyP) regions. The region between 400 to 
600 amino acids contains many endoproteolytic sites for proteases such as caspases 2, 
3, 6, calpain, and matrix metalloproteinase 10 (MMP-10). Approximately 16 HEAT 
repeats have been identified in Htt with unknown function. The C-terminal region 
consists of a leucine-rich nuclear export signal (NES), which could target the full-
length Htt to the cytoplasm.  
Figure 4 PrP cleavage sites 
Schematic representation of the prion protein. The N-terminus is structurally 
disordered contains a signal peptide and an octameric repeat region. The C-terminus 
is structurally ordered consisting of three α-helixes and two β-strands, a disulphide 
bond (-S-S-). A glycosylphosphatidylinositol (GPI) anchor that anchors the prion 
protein at the cell surface is found at the C-terminus. The endoproteolytic cleavage 
sites are indicated. 
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